drugset / Trial / NCT01701518
A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
Unknown
15 enrolled
Sunnybrook Health Sciences Centre
Allergan · collabUnity Health Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine if an intravitreal sustained release dexamethasone implant (Ozurdex®) injected at the conclusion of surgery in patients undergoing vitrectomy and membrane peeling for idiopathic epiretinal membranes is safe and effective to decrease the macular edema, as demonstrated by a gain in vision and decreased in retinal thickness and volume.
Timeline
- Start
- 2012-10
- Primary completion
- 2016-03
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.7 mg | Intravitreal |